<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04782895</url>
  </required_header>
  <id_info>
    <org_study_id>HPV-PRO-011</org_study_id>
    <nct_id>NCT04782895</nct_id>
  </id_info>
  <brief_title>Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age</brief_title>
  <official_title>A Randomized, Single-blind Study to Compare Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) (Xiamen Innovax Biotech Co.,Ltd.) Versus Gardasil®9 (Merck &amp; Co., Inc.) in Healthy Females 18-26 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiamen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xiamen Innovax Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xiamen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the immunogenicity of a novel recombinant human&#xD;
      papillomavirus vaccine (types 6,11,16,18,31,33,45,52,58 )(E.Coli) manufactured by Xiamen&#xD;
      Innovax Biotech CO., Ltd., with Gardasil®9 in females 18-26 Years of Age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 14, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific neutralizing antibody level</measure>
    <time_frame>7 months after the first dose</time_frame>
    <description>Anti-HPV 6,11,16,18,31,33,45,52 and 58 seroconversion rates and geometric mean concentrations at months 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety1:Local and systematic adverse events/reactions occurred within 7 days after each vaccination.</measure>
    <time_frame>During the 7-day period following each vaccination</time_frame>
    <description>Local and systematic adverse events/reactions occurred within 7 days after each vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety2:Adverse events/reactions occurred within 30 days after each vaccination.</measure>
    <time_frame>Within 30 days (Day 0-30) after any vaccination</time_frame>
    <description>Adverse events/reactions occurred within 30 days after each vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety3:Severe adverse events occurred throughout the study. To evaluate number of SAEs compared with the control vaccine.</measure>
    <time_frame>Up to 8 month</time_frame>
    <description>Severe adverse events occurred throughout the study. To evaluate number of SAEs compared with the control vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety4:Pregnancy and pregnancy outcome. To evaluate number of births and terminations compared with the control vaccine.</measure>
    <time_frame>Up to 8 month</time_frame>
    <description>Pregnancy and pregnancy outcome. To evaluate number of births and terminations compared with the control vaccine.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific IgG antibody level</measure>
    <time_frame>7 months after the first dose</time_frame>
    <description>Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations at months 7(type specific IgG antibody)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">488</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Condylomata Acuminata</condition>
  <arm_group>
    <arm_group_label>Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects would receive 3 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gardasil®9 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects would receive 3 doses of 270μg/0.5ml Gardasil®9 .</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)</intervention_name>
    <description>Three doses administered intramuscularly at 0, 45 day and 6 month.</description>
    <arm_group_label>Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil®9</intervention_name>
    <description>Three doses administered intramuscularly at 0, 45 day and 6 month.</description>
    <arm_group_label>Gardasil®9 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is female, between and including 18-26 years of age at the first vaccination;&#xD;
&#xD;
          2. Subject is able to understand and comply with the requirements of the protocol(e.g.&#xD;
             biological specimen collection, completion of the diary cards, return for follow-up&#xD;
             visits), and written informed consent must be obtained from the subject prior to&#xD;
             enrollment;&#xD;
&#xD;
          3. Subject who agrees to practice effective contraception within 8 months after the first&#xD;
             vaccination or has undergone tubal ligation,subtotal hysterectomy for benign lesion,&#xD;
             ovarian benign tumor resection;&#xD;
&#xD;
          4. No previous history of sexually transmitted diseases (including syphilis, gonorrhea,&#xD;
             chancroid, venereal lymphogranuloma, groin granuloma, etc.);&#xD;
&#xD;
          5. No previous history of abnormal cervical screening results or cervical intraepithelial&#xD;
             neoplasia (CIN);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Axillary temperature &gt; 37.0℃;&#xD;
&#xD;
          2. Subject who has a positive urine pregnancy test, or is pregnant or breastfeeding;&#xD;
&#xD;
          3. Subject has used of any investigational or non-registered product (drug or vaccine)&#xD;
             within 30 days preceding the first dose of study vaccine or plans to use during the&#xD;
             study period , or has participated in another clinical research in the past two years,&#xD;
             or plans to participate in another research during the study period;&#xD;
&#xD;
          4. Chronic administration (defined as more than 14 days) of immunosuppressants or other&#xD;
             immune-modifying drugs or systemic corticosteroids (Except intranasal steroid, the use&#xD;
             of low dose topical, ophthalmic and inhaled steroid preparations will be permitted.)&#xD;
             within 6 months prior to vaccination.&#xD;
&#xD;
          5. Administration of immunoglobulin and/or blood products within 3 months prior to&#xD;
             vaccination or planned to use them within 7 months after the first dose.&#xD;
&#xD;
          6. Administration of inactivated vaccine within 14 days prior to vaccination or live&#xD;
             vaccine within 21 days;&#xD;
&#xD;
          7. Fever (Axillary temperature ≥38.0℃) 3 days prior to vaccination or system&#xD;
             administration of antibiotics or antiviral agents within 5 days prior to vaccination;&#xD;
&#xD;
          8. Subject has received other HPV vaccines or participated in clinical research related&#xD;
             to HPV or cervical cancer previously;&#xD;
&#xD;
          9. Subject has immunodeficiency disease, primary disease of important viscera, cancer and&#xD;
             autoimmune disease (including systemic lupus erythematosus, rheumatoid arthritis,&#xD;
             asplenia or splenectomy due to any condition, and other immunological diseases that&#xD;
             investigators believe may influence the immune response).&#xD;
&#xD;
         10. History of severe allergy (e.g., anaphylaxis, generalized urticaria, dyspnea,&#xD;
             angioedema, and other significant reaction) to any previous vaccination, or be&#xD;
             allergic to any of the components of the study vaccines.&#xD;
&#xD;
         11. Asthma, which has been unstable for the past two years and requires emergency&#xD;
             treatment, hospitalization, oral or intravenous corticosteroids;&#xD;
&#xD;
         12. Subject has Serious medical disorders;&#xD;
&#xD;
         13. Self-report coagulation disorders or abnormal coagulation function;&#xD;
&#xD;
         14. Epilepsy, excluding febrile epilepsy under 2 years of age, alcoholic epilepsy 3 years&#xD;
             prior to abstinence or simple epilepsy that does not require treatment in the past 3&#xD;
             years;&#xD;
&#xD;
         15. Medical, psychological, social conditions, occupation or other factors, which&#xD;
             considered by the investigator that may influence the conduct of the clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhang, master</last_name>
    <role>Study Chair</role>
    <affiliation>Xiamen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Feng-cai Zhu, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Provincial Centre for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jiangsu Provincial Centre for Disease Control and Prevention</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xiamen University</investigator_affiliation>
    <investigator_full_name>Jun Zhang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>human papillomavirus vaccine</keyword>
  <keyword>immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

